Sisi Wu1, Tao Yang2, Youfu Luo2, Xiaolu Li3, Xian Zhang2, Jianying Tang2, Xiuying Ma2, Zhenling Wang4. 1. Molecular Medicine Research Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China. 2. State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, China. 3. Institute of Burn Research, Southwest Hospital, Third Military Medical University, Chongqing 400038, China. 4. State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, China wangzhenling@scu.edu.cn.
Abstract
OBJECTIVES: Infections of hospitalized patients caused by biofilms formed by Staphylococcus aureus represent a major problem. Using in vitro and in vivo biofilm models, we evaluated the efficacy of the novel oxazolidinone FYL-67, by using linezolid (the only clinically approved oxazolidinone antibiotic) as a control, for inhibiting S. aureus biofilm formation. METHODS: Antibiofilm activity was determined using strains of methicillin-susceptible S. aureus and methicillin-resistant S. aureus. We studied the mechanism(s) and pharmacodynamics of antibiofilm activity as follows: (i) effects of pre- and post-exposure to FYL-67 or linezolid on biofilm formation; (ii) the effect of FYL-67 on biofilm structure; (iii) the role of FYL-67 in biofilm composition; (iv) effects on cell morphology; and (v) efficacy of FYL-67 and linezolid using an in vivo murine model of catheter infection. RESULTS: FYL-67 effectively inhibited biofilm formation using in vitro and in vivo assays. CONCLUSIONS: Our data suggest that oxazolidinone compounds, such as FYL-67, may serve as antibiofilm agents.
OBJECTIVES: Infections of hospitalized patients caused by biofilms formed by Staphylococcus aureus represent a major problem. Using in vitro and in vivo biofilm models, we evaluated the efficacy of the novel oxazolidinone FYL-67, by using linezolid (the only clinically approved oxazolidinone antibiotic) as a control, for inhibiting S. aureus biofilm formation. METHODS: Antibiofilm activity was determined using strains of methicillin-susceptible S. aureus and methicillin-resistant S. aureus. We studied the mechanism(s) and pharmacodynamics of antibiofilm activity as follows: (i) effects of pre- and post-exposure to FYL-67 or linezolid on biofilm formation; (ii) the effect of FYL-67 on biofilm structure; (iii) the role of FYL-67 in biofilm composition; (iv) effects on cell morphology; and (v) efficacy of FYL-67 and linezolid using an in vivo murine model of catheter infection. RESULTS:FYL-67 effectively inhibited biofilm formation using in vitro and in vivo assays. CONCLUSIONS: Our data suggest that oxazolidinone compounds, such as FYL-67, may serve as antibiofilm agents.
Authors: S Albac; M Medina; D Labrousse; D Hayez; D Bonnot; N Anzala; F Laurent; T Ferry; A Dublanchet; P Chavanet; C Fevre; D Croisier Journal: Antimicrob Agents Chemother Date: 2020-01-27 Impact factor: 5.191